TerrAscend (TSNDF) Non-Current Deferred Tax Liability (2021 - 2026)
TerrAscend (TSNDF) posted quarterly Non-Current Deferred Tax Liability of $8.3 million for Q1 2026, down 6.3% year-over-year from $8.9 million in Q1 2025, and up 3.74% quarter-over-quarter from $8.0 million in Q4 2025.
TerrAscend (TSNDF) Non-Current Deferred Tax Liability (2021 - 2026) Analysis & Trends
TerrAscend (TSNDF) has reported Non-Current Deferred Tax Liability for 6 consecutive years, with $8.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability fell 6.3% year-over-year to $8.3 million; the TTM figure through Mar 2026 stood at $8.3 million (down 6.3% YoY), while the FY2025 annual figure was $8.0 million, down 4.78% from the prior year.
- Non-Current Deferred Tax Liability improved to $8.3 million in Q1 2026 per TSNDF's latest filing, from $8.0 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $73.1 million in Q2 2022 and bottomed at $8.0 million in Q4 2025.
- Historically, Non-Current Deferred Tax Liability has averaged $26.1 million across 5 years, with a median of $16.9 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability jumped 115.15% — and 2024, when it slumped 57.68%.
- TerrAscend's Non-Current Deferred Tax Liability stood at $30.7 million in 2022, then tumbled by 44.06% to $17.2 million in 2023, then plunged by 50.93% to $8.4 million in 2024, then retreated by 4.78% to $8.0 million in 2025, then grew by 3.74% to $8.3 million in 2026.
- Business Quant data shows TSNDF's Non-Current Deferred Tax Liability at $8.3 million in Q1 2026, $8.0 million in Q4 2025, and $8.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - |
| 10 | TerrAscend | 187.35 Mn | 145.23 Mn | 36.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.90 Mn |
| Jun 30, 2026 | 11.90 Mn |
| Mar 31, 2026 | 8.33 Mn |
| Mar 31, 2026 | 8.33 Mn |
| Dec 31, 2025 | 8.03 Mn |
| Dec 31, 2025 | 8.03 Mn |
| Sep 30, 2025 | 8.72 Mn |
| Sep 30, 2025 | 8.72 Mn |
| Jun 30, 2025 | 9.03 Mn |
| Jun 30, 2025 | 9.03 Mn |
| Mar 31, 2025 | 8.89 Mn |
| Mar 31, 2025 | 8.89 Mn |
| Dec 31, 2024 | 8.43 Mn |
| Dec 31, 2024 | 8.43 Mn |
| Sep 30, 2024 | 16.19 Mn |
| Sep 30, 2024 | 16.19 Mn |
| Jun 30, 2024 | 16.76 Mn |
| Jun 30, 2024 | 16.76 Mn |
| Mar 31, 2024 | 16.92 Mn |
| Mar 31, 2024 | 16.92 Mn |